Joel Lewis Sells 37,698 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) CEO Joel Lewis sold 37,698 shares of the firm’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $3.58, for a total transaction of $134,958.84. Following the completion of the sale, the chief executive officer owned 832,592 shares of the company’s stock, valued at $2,980,679.36. This trade represents a 4.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Joel Lewis also recently made the following trade(s):

• On Monday, January 5th, Joel Lewis sold 27,731 shares of Galectin Therapeutics stock. The stock was sold at an average price of $3.91, for a total value of $108,428.21.
• On Friday, January 2nd, Joel Lewis sold 18,571 shares of Galectin Therapeutics stock. The shares were sold at an average price of $4.20, for a total value of $77,998.20.
• On Wednesday, December 17th, Joel Lewis sold 7,829 shares of Galectin Therapeutics stock. The stock was sold at an average price of $7.06, for a total transaction of $55,272.74.
• On Wednesday, November 5th, Joel Lewis sold 200 shares of Galectin Therapeutics stock. The stock was sold at an average price of $6.00, for a total transaction of $1,200.00.
• On Tuesday, November 4th, Joel Lewis sold 14,420 shares of Galectin Therapeutics stock. The stock was sold at an average price of $6.07, for a total value of $87,529.40.
• On Monday, November 3rd, Joel Lewis sold 1,300 shares of Galectin Therapeutics stock. The shares were sold at an average price of $6.01, for a total value of $7,813.00.

Galectin Therapeutics Trading Up 2.6%

NASDAQ:GALT opened at $3.54 on Thursday. The firm has a 50-day moving average price of $5.27 and a two-hundred day moving average price of $4.39. Galectin Therapeutics Inc. has a twelve month low of $1.07 and a twelve month high of $7.13. The company has a market capitalization of $228.23 million, a P/E ratio of -6.00 and a beta of 1.03.

Galectin Therapeutics (NASDAQ:GALT) last posted its earnings results on Friday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, equities research analysts predict that Galectin Therapeutics Inc. will post -0.73 earnings per share for the current year.

Institutional Trading of Galectin Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. grew its holdings in shares of Galectin Therapeutics by 25.4% during the third quarter. JPMorgan Chase & Co. now owns 15,470 shares of the company’s stock valued at $66,000 after purchasing an additional 3,133 shares during the last quarter. Hudson Bay Capital Management LP bought a new stake in Galectin Therapeutics during the third quarter worth approximately $63,000. Vivaldi Capital Management LP boosted its stake in Galectin Therapeutics by 48.3% during the third quarter. Vivaldi Capital Management LP now owns 255,752 shares of the company’s stock valued at $1,083,000 after buying an additional 83,309 shares in the last quarter. Qube Research & Technologies Ltd lifted its stake in Galectin Therapeutics by 290.9% during the third quarter. Qube Research & Technologies Ltd now owns 60,867 shares of the company’s stock valued at $258,000 after purchasing an additional 45,297 shares during the last quarter. Finally, Lido Advisors LLC acquired a new stake in shares of Galectin Therapeutics during the third quarter worth $154,000. Institutional investors own 11.68% of the company’s stock.

Wall Street Analyst Weigh In

GALT has been the topic of several recent analyst reports. HC Wainwright increased their target price on Galectin Therapeutics from $6.00 to $11.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Galectin Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $11.00.

More Galectin Therapeutics News

Here are the key news stories impacting Galectin Therapeutics this week:

• Positive Sentiment: Analyst upgrade: HC Wainwright raised its price target and reiterated a “buy” on GALT in mid‑December, supporting upside sentiment and providing a bullish research anchor for the stock. MarketBeat – Analyst Note
• Neutral Sentiment: Institutional activity: small/new positions were reported from several funds (Nuveen, Atwood & Palmer, Hudson Bay, etc.) and Bank of America increased its stake; institutional ownership remains low (~11.7%) so impact is limited but worth monitoring. MarketBeat – Institutional Holdings
• Negative Sentiment: Regulatory / litigation risk: The Schall Law Firm and Pomerantz LLP announced investigations into Galectin that allege potential securities law violations; such probes typically increase legal risk and can pressure the stock until clarified. Schall Law Firm Investigation
• Negative Sentiment: Large, clustered insider selling: CEO Joel Lewis, CFO Jack Callicutt and insider Khurram Jamil sold sizable blocks across Jan. 2–6 (multiple Form 4s), trimming their ownership and raising concerns about insider sentiment or liquidity needs. Multiple filings may weigh on investor confidence. Form 4 – Joel Lewis
• Negative Sentiment: Insider sale summaries: CFO and other insiders sold tens of thousands of shares at prices between about $3.58–$4.20 in the same window; repeated insider sales amplify downside risk until rationale (e.g., diversification or personal liquidity) is disclosed. InsiderTrades – Sales Summary

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.